Epiq Capital Group, LLC Cyclo Therapeutics, Inc. Transaction History
Epiq Capital Group, LLC
- $331 Million
- Q3 2024
A detailed history of Epiq Capital Group, LLC transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Epiq Capital Group, LLC holds 739,426 shares of CYTH stock, worth $465,838. This represents 0.18% of its overall portfolio holdings.
Number of Shares
739,426
Previous 817,270
9.52%
Holding current value
$465,838
Previous $1.04 Million
43.68%
% of portfolio
0.18%
Previous 0.39%
Shares
3 transactions
Others Institutions Holding CYTH
# of Institutions
20Shares Held
2.25MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA599KShares$377,1770.0% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$302,8467.36% of portfolio
-
Geode Capital Management, LLC Boston, MA152KShares$95,9690.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$69,31418.16% of portfolio
-
Black Rock Inc. New York, NY59.5KShares$37,4910.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $5.32M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...